Invitae Corp false 0001501134 0001501134 2021-02-03 2021-02-03












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report: February 3, 2021

(Date of earliest event reported)



Invitae Corporation

(Exact name of registrant as specified in its charter)




Delaware   001-36847   27-1701898

(State or other jurisdiction of

incorporation or organization)



File Number)


(I.R.S. employer

identification number)

1400 16th Street, San Francisco, California 94103

(Address of principal executive offices, including zip code)

(415) 374-7782

(Registrant’s telephone number, including area code)


(Former Name or Former Address, if Changed Since Last Report.)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   NVTA   The New York Stock Exchange LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 8.01

Other Events.

Jason W. Myers, Ph.D., who has been leading the oncology team at Invitae Corporation (the “Company”) since the Company’s acquisition of ArcherDX, Inc. (“ArcherDX”) in October 2020, has notified the Company that he will be stepping down from his operating role to accept the CEO position at Genapsys, Inc., a privately held genomic sequencing technology company, effective February 15, 2021. Dr. Myers will continue to serve as a member of the Company’s Board of Directors (the “Board”).

Dr. Myers, the former CEO and director of ArcherDX, has played an active role in the integration of ArcherDX into the Company. The Company’s integrated team of leaders will continue the Company’s oncology development efforts.

The Board and the entire leadership team wish Dr. Myers the very best in his new role and look forward to continuing to work with him as a member of the Board.


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Date: February 3, 2021     By:  

/s/ Thomas R. Brida

    Name:   Thomas R. Brida
    Title:   General Counsel